Ferrer, Ana
Mayo Clinic
Hematology Department, IMIM-Hospital del Mar, Barcelona, Spain.
Citations 1
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Clot, Guillem , Jares, Pedro , Giné, Eva , Navarro, Alba , Pinyol, Magda, Martin‐García, David , Demajo, Santiago , Espinet, Blanca , Salar, Antonio , Ferrer, Ana , Muntañola, Ana , Aymerich, Marta , Rauert‐Wunderlich, Hilka , Gascoyne, Randy D. , Delabie, Jan , López‐Guillermo, Armando , Ott, German , Wright, George W. , Staudt, Louis M. , Rosenwald, Andreas , Beà, Sı́lvia , Martín-Garcia, David , Demajo, Santiago , Salar, Antonio , Ferrer, Ana , Jaffe, Elaine S , Connors, Joseph M , Delabie, Jan , López-Guillermo, Armando , Beà, Sílvia , Campo, Elías , Royo, Cristina , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Rimsza, Lisa M. , Campo, Elı́as , Espinet, Blanca , Wright, George
Blood | May 16, 2018 | Volume: 132 | Issue: 4 | Pages: 413-422
Key PointsA new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.